EODData

MEMBERSHIP REGISTER LOG IN

OTCBB, KHTRF: Knight Therapeutics Inc

11 Nov 2025
LAST:

4.370

CHANGE:
 0.07		OPEN:
4.370		HIGH:
4.370		ASK:
0.000		VOLUME:
50.1K
CHG(%):
1.60		PREV:
4.301		LOW:
4.370		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
11 Nov 254.3704.3704.3704.37050.1K
07 Nov 254.3014.3014.3014.3011.0K
06 Nov 254.2584.2584.2584.2589.1K
05 Nov 254.1454.1454.1454.145600
04 Nov 254.1304.1304.1304.1305.0K
03 Nov 254.1594.1594.1594.1595.8K
31 Oct 254.1464.1604.1464.1603.2K
30 Oct 254.1284.1284.1284.1281.9K
29 Oct 254.1744.1744.1744.17413.5K
28 Oct 254.1924.1924.1924.1922.3K

COMPANY PROFILE

Name:Knight Therapeutics Inc
About:Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson's disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson's disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, the company finances other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.
Sector:Healthcare
Address:3400 de Maisonneuve Blvd. W., Montreal, QC, Canada, H3Z 3B8
Website:https://www.knighttx.com
CIK:0001756235
FIGI:BBG0068Q74Y7

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:4.243.0%
MA10:4.204.0%
MA20:4.174.7%
MA50:4.350.6%
MA100:4.223.5%
STO9:100.00 
STO14:100.00 
RSI14:72.43 
MTM14:0.20
ROC14:0.05 
ATR:0.04 
Week High:4.370.0%
Week Low:4.135.8%
Month High:4.370.0%
Month Low:4.07